Drugs / ChAdOx1 nCoV-19 vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05133609 | Jan 2021 → Aug 2022 | COVID-19 | Federal University of Espirito Santo | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04730895 Comparator | Jul → Sep 2021 | — | Kafrelsheikh University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ChAdOx1 nCoV-19 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05133609 ↗ |
| Known as | AZD1222 | “ChAdOx1 nCoV-19 vaccine (AZD1222)” NCT05133609 ↗ |
| Modality | Vaccine | “spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine” NCT04730895 ↗ |